Darnytsa (Kyiv) pharmaceutical company in 2022 slightly reduced the production of drugs in physical terms – from 181 mln packs in 2021 to 173 mln packs in 2022, as the company informed Interfax-Ukraine news agency.
At the same time, according to its press release, Darnitsa occupies 15.7% of the Ukrainian pharmaceutical market, twice as much as its closest competitor.
“If in 2021 every seventh pack of drugs sold in pharmacies was made by “Darnitsa”, then in 2022 it is every sixth pack,” – according to the press release.
In total, in 2022 the company produced about 19 million packages of ampoules, 9 million packages of infusion solutions and 130 million packages of tablets and capsules.
At the same time, it is noted that “Darnitsa” has not stopped working since the first days of the full-scale war. In March it produced 60% of the pre-war volume of drugs, and in April it returned to pre-war production volumes in full.
PJSC “Pharmaceutical company “Darnitsa” is the leader of Ukrainian pharmaceutical market in physical terms. The company has been on the market for more than 90 years and manufactures 180 brands of drugs in 15 different forms. Strategic directions of portfolio development – cardiology, neurology, pain management.
The company was founded in 1930. According to the Uniform State Register of Legal Entities and Individual Entrepreneurs, the company’s ultimate beneficiary is Gleb Zagori.
Darnitsa pharmaceutical company (Kyiv), within the framework of cooperation with the Ministry of Health of Ukraine and the National Security and Defense Council, has registered and produced the drug Potassium Iodide-125-Darnitsa, designed to protect people from radiation, Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, wrote about this on Facebook.
He said that the drug was created in accordance with the regulations for iodine prophylaxis in the event of a radiation accident.
In addition, Shymkiv said that last week Darnitsa donated 525,000 packages (5.25 million tablets) from the first batch of Potassium Iodide-125-Darnitsa to the public health center of the Ministry of Health for free. This will make it possible to carry out iodine prophylaxis if necessary for more than 5 million people.
Potassium iodide is used to protect the thyroid from radiation buildup. The risk of radiation damage to the thyroid gland can be reduced or even leveled with the timely appointment of iodine prophylaxis. The optimal effect of iodine prophylaxis is achieved with preventive intake of potassium iodide for 6 hours or less, as well as simultaneously with the intake of radioactive isotopes of iodine or entering the contaminated zone.
The pharmaceutical company Darnitsa invested EUR10 million in technological projects in 2019, Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, has said.
“In 2019, we invested EUR10 million in technology projects, research, development and production of new drugs. This is 24% more than in 2018,” he said in an interview with Interfax-Ukraine.
Shymkiv said that the structure of Darnitsa’s investments includes three areas: about 48% is investment in new products, 34% in technological development and 16% in digitalization.
Darnitsa invested EUR 2.33 million in digitalization, and more than EUR 30 million in new products in 2015-2019.
He noted that in 2020, Darnitsa launched nine new products in therapeutic areas such as cardiology, neurology, mental health, and completed eight bioequivalence studies of its drugs in the EU, six more studies are ongoing.
Darnitsa pharmaceutical company has suspended a project for the production of hydroxychloroquine for the treatment of COVID-19.
Аccording to the press service of the company, the company came to such a decision by tracking reputable medical studies regarding the effectiveness of hydroxychloroquine in the treatment of COVID-19. In particular, as of May 26, some 201 studies of the use of hydroxychloroquine for the treatment of COVID-19 were recorded, of which five were completed.
The company notes that the published clinical trial materials have not confirmed the benefits of using the experimental drug ‘hydroxychloroquine’ for patients with COVID-19.
“The safety of patients and scientific feasibility is an absolute priority for the company. Therefore, taking into account the world scientific thought, the company suspended the project for the production of hydroxychloroquine for the treatment of COVID-19,” Darnitsa said.
The company reminds that Darnitsa had launched the project to prepare for the production of hydroxychloroquine in March 2020, when Chinese treatment protocols and publications in authoritative sources about the effectiveness of this drug for the treatment of COVID-19 appeared. These data gave reason to include hydroxychloroquine in the protocols of experimental treatment of COVID-19 in many countries of the world, in particular in Ukraine, the United States and in European countries.
“At the same time, Darnitsa received numerous requests from Ukrainian doctors and patients asking for the opportunity to use the drug for treating coronavirus infection, since this therapy was considered by the medical community as potentially effective. Considering the scientific data and the medical community’s requests, Darnitsa started a project for the production of hydroxychloroquine preparations exclusively for the needs of medical institutions in the treatment of COVID-19,” the company’s press service said.
Darnitsa pharmaceutical company was founded in 1930. It is one of the ten largest pharmaceutical manufacturers in Ukraine and the top ten largest hospital suppliers. The strategic directions of the portfolio development are cardiology, neurology and solutions to pain problems.
Darnitsa pharmaceutical company in 2018 invested about EUR3.5 million in development and research (R&D), Dmytro Shymkiv, the head of the board of directors of Darnitsa Group, has said.
“Every year we invest about 10% of gross income in development and research. In 2018 the amount of such investments totaled EUR 3.5 million. In total, Darnitsa invested about EUR 200 million in development,” he said at a press conference in Kyiv.
Shymkiv said that in 2020-2022 Darnitsa plans to conduct 9-12 drug bioequivalence studies.
Since 2016, the company has completed eight such studies.
According to him, the development strategy of Darnitsa provides for three priority areas of the product portfolio: cardiology, neurological drugs, and pain therapy.
In 2019, the pharmaceutical company plans to bring 11 brands to the market, in 2020 some 14. In 2018, Darnitsa brought ten brands to the market.
Currently, the company’s product portfolio comprises 250 types of finished medicines.
Darnitsa pharmaceutical company is one of the ten largest pharmaceutical manufacturers in Ukraine and the top ten largest hospital suppliers. Its ultimate beneficiary is Hlib Zahoriy.
Darnitsa pharmaceutical company plans to develop in foreign markets, in particular through the acquisition of companies or joint development. This was reported by head of the board of directors of Darnitsa Group Dmytro Shymkiv in Kyiv. He noted that the purchase of foreign companies is one of the “instruments to increase the share of exports.”
According to him, Darnitsa is currently conducting due diligence of several companies, and although Shymkiv did not provide details, he added that the company is studying the issue of acquiring companies not only abroad.
Currently, Darnitsa has about 365 registrations in foreign markets.
“Not all Ukrainian pharmaceutical manufacturers will withstand the requirements for 2D coding of pharmaceutical packaging. In 2020, we will see interesting processes in the Ukrainian market,” he said.
According to him, in 2020 the company plans to invest about EUR4 million in development and research.
As reported, in 2018 Darnitsa invested about EUR3.5 million in development and research, while annually the company invests about 10% of gross income in this direction.
Darnitsa pharmaceutical company is one of the ten largest pharmaceutical manufacturers in Ukraine and the top ten largest hospital suppliers. Its ultimate beneficiary is Hlib Zahoriy.
